Susan Lindquist - Johnson Johnson Independent Director
| JNJ Stock | EUR 140.06 0.94 0.67% |
Director
Dr. Susan L. Lindquist, Ph.D., is an Independent Director of Johnson And Johnson. She joined the Board of Directors in 2004 and is Chairman of the Science, Technology Sustainability Committee and a member of the Regulatory, Compliance Government Affairs Committee. She is a member of the Whitehead Institute, a nonprofit, independent research and educational institution, a Professor of Biology at the Massachusetts Institute of Technology and an Investigator of the Howard Hughes Medical Institute. Dr. Lindquist served as Director of the Whitehead Institute from 2001 to 2004. Previously she was affiliated with the University of Chicago where she was the Albert D. Lasker Professor of Medical Sciences in the Department of Molecular Genetics and Cell Biology. Dr. Lindquist was elected to the American Academy of Arts and Sciences in 1996, the National Academy of Sciences in 1997, the American Philosophical Society in 2003 and the Institute of Medicine in 2006. She received the NovartisDrew Award for Biomedical Research in 2000, the Dickson Prize in Medicine in 2002, the Sigma Xi William Procter Prize for Academic Achievement in 2006, the Nevada Silver Medal for Scientific Achievement in 2007, the Genetics Society of America Medal and the Centennial Medal of the Harvard University Graduate School of Arts and Sciences in 2008. In 2010, she received the Mendel Medal from the Genetics Society, The Delbrck Medal from Bayer Schering, and the National Medal of Science . In 2012, Dr. Lindquist received the Wilson Medal in Cell Biology and in 2013 the Dart Prize in Biotechnology. She has served on the Scientific Advisory boards of many independent research institutes, associations and foundations, including the Massachusetts General Hospital, Brigham and Womens Hospital and the Institute fr Molekulare Biotechnology GmbH since 2004.
| Age | 65 |
| Tenure | 20 years |
| Phone | 732 524 0400 |
| Web | https://www.jnj.com |
Johnson Johnson Management Efficiency
The company has return on total asset (ROA) of 0.0871 % which means that it generated a profit of $0.0871 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2379 %, meaning that it generated $0.2379 on every $100 dollars invested by stockholders. Johnson Johnson's management efficiency ratios could be used to measure how well Johnson Johnson manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0871 |
Johnson Johnson Leadership Team
Elected by the shareholders, the Johnson Johnson's board of directors comprises two types of representatives: Johnson Johnson inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Johnson. The board's role is to monitor Johnson Johnson's management team and ensure that shareholders' interests are well served. Johnson Johnson's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Johnson Johnson's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dirk Brinckman, Chief Officer | ||
| Jennifer Doudna, Independent Director | ||
| Alex Gorsky, Chairman of the Board, CEO | ||
| William Perez, Independent Director | ||
| Michael Sneed, Executive Vice President - Global Corporate Affairs and Chief Communication Officer | ||
| Marillyn Hewson, Independent Director | ||
| Jorge Mesquita, Executive Vice President Worldwide Chairman - Consumer | ||
| Mary Coleman, Independent Director | ||
| Michael Ullmann, Vice President General Counsel | ||
| Joaquin Duato, Executive Vice President Worldwide Chairman - Pharmaceuticals | ||
| Joseph CPA, Ex CFO | ||
| Kathy Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| Jennifer Taubert, Executive Vice President - Worldwide Chairman, Pharmaceuticals | ||
| Mary Beckerle, Director | ||
| Sandra Peterson, Group Worldwide Chairman | ||
| Scott Davis, Director | ||
| Louise Mehrotra, Vice President Investor Relations | ||
| Robert Decker, Controller Officer | ||
| Ashley McEvoy, Executive Vice President - Worldwide Chairman, Medical Devices | ||
| Ronald Williams, Independent Director | ||
| Kathryn Wengel, Executive Vice President Chief Global Supply Chain Officer | ||
| James Swanson, Ex Officer | ||
| Anne Mulcahy, Lead Independent Director | ||
| Joseph Wolk, Vice President - Investor Relations | ||
| Thibaut Mongon, Executive Vice President Worldwide Chairman, Consumer | ||
| Jessica Moore, VP Relations | ||
| Ian Davis, Independent Director | ||
| Paulus Stoffels, Chief Scientific Officer, Worldwide Chairman - Pharmaceuticals Group | ||
| Mark McClellan, Independent Director | ||
| Charles Prince, Independent Director | ||
| Eugene Washington, Independent Director | ||
| Elizabeth Forminard, Exec Counsel | ||
| Dominic Caruso, CFO, Vice President - Finance | ||
| Peter Fasolo, Vice President - Global Human Resources | ||
| Susan Lindquist, Independent Director |
Johnson Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Johnson Johnson a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.24 | |||
| Return On Asset | 0.0871 | |||
| Profit Margin | 0.19 % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 443.95 B | |||
| Shares Outstanding | 2.6 B | |||
| Shares Owned By Insiders | 0.09 % | |||
| Shares Owned By Institutions | 71.60 % | |||
| Price To Earning | 29.33 X | |||
| Price To Book | 6.28 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Johnson Johnson in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Johnson Johnson's short interest history, or implied volatility extrapolated from Johnson Johnson options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Johnson Johnson. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. For more detail on how to invest in Johnson Stock please use our How to Invest in Johnson Johnson guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Johnson Stock analysis
When running Johnson Johnson's price analysis, check to measure Johnson Johnson's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Johnson Johnson is operating at the current time. Most of Johnson Johnson's value examination focuses on studying past and present price action to predict the probability of Johnson Johnson's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Johnson Johnson's price. Additionally, you may evaluate how the addition of Johnson Johnson to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing |